Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 212-218

  Nadler, Eric ^a   Forsyth, Michael ^a   Satram Hoang, Sacha ^b   Reyes, Carolina ^b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b GENENTECH INC   (United States)

Author keywords

Costs; Non small cell; Outcomes

Indexed keywords

DOCETAXEL; ERLOTINIB; HEMOGLOBIN; PEMETREXED;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER STAGING; COMMUNITY CARE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; EMERGENCY CARE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT CARE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; REIMBURSEMENT; SEX RATIO; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84655160801     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182307f33     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts & Figures 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ acspc-024113.pdf. Accessed August 2, 2010.
2. Surveillance Epidemiology and End Results (SEER). Stat bite: lung cancer stage at diagnosis in the United States, 1995-2001. J Natl Cancer Inst 2005;97:1805.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer V. 2.2010, 2010.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353. (Pubitemid 41095099)
5. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:277S-289S. (Pubitemid 47502813)
6. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123:226S- 243S. (Pubitemid 36135720)
7. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005;10(Suppl 3):1-10. (Pubitemid 43152725)
8. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2006;24:3831-3837. (Pubitemid 46630729)
9. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004;43:183-194. (Pubitemid 38114747)
10. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008;13(Suppl 1):14-20.
11. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362. (Pubitemid 30415821)
12. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
13. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
15. Eli Lilly and Company. Alimta (pemetrexed) prescribing information, 2010.
16. Genentech USA Inc. Tarceva (erlotinib) prescribing information, 2010.
17. sanofi-aventis U.S. LLC. Taxotere (docetaxel) prescribing information, 2010.
18. Chouaid C, Atsou K, Hejblum G, et al. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 2009;27:113-125.
19. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003;3:435-442. (Pubitemid 37009843)
20. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008;61:405-415.
21. Lyseng-Williamson KA. Erlotinib: A pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010; 28:75-92.
22. Ramsey SD, Clarke L, Kamath TV, et al. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 2006;12:472-478.
23. Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008; 14:297-306.
24. Lash S, Teitelbaum A, Henk H, et al. Costs associated with second-line therapies for lung cancer. Am J Pharm Benefits 2011;3:101-113.
25. Ciuleanu T, Stelmakh L, Cicenas S, et al. Erlotinib versus Docetaxel or Pemetrexed as Second-Line Therapy in Patients with Advanced Non- Small-Cell Lung Cancer (NSCLC) and Poor Prognosis: Efficacy and Safety Results from the Phase III TITAN study. IASLC, Geneva, Switzerland, 2010.
26. Vamvakas L, Agelaki S, Kentepozidis N, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol 2010;28:(suppl; abstr 7519).